FINWIRES · TerminalLIVE
FINWIRES

Opthea Poised to Resume Trading on Australian Securities Exchange After Decision to Advance Lung Disease Drug Candidate

By

Opthea (ASX:OPT) expects to resume trading on the Australian Securities Exchange on or around Wednesday following a decision to advance its OPT-302 drug candidate for the treatment of lymphangioleiomyomatosis, according to a same-day filing with the Australian bourse.

Lymphangioleiomyomatosis is a chronic lung disease that mainly affects women, characterized by the destruction of lung tissue.

Opthea believes its scientific assets, manufacturing capabilities, and intellectual property portfolio "provide a strong foundation" for a strategy focused on the disease, where a significant unmet medical need exists.

The company has launched a staged development program over an expected 18-month period to evaluate OPT-302, it said.

Related Articles

Asia

Tata Motors Passenger Vehicles' Total Sales Rise 42% in May

Tata Motors Passenger Vehicles' (NSE:TMPV, BOM:500570) total sales rose 42% to 59,790 units in May, against 42,040 units sold a year ago, according to a Monday filing to the Indian bourses.Total domestic sales in May also grew 42% to 59,090 units from 41,557 units a year earlier, the filing said.Of the total, electric vehicle sales jumped 85% year-on-year to 10,517 units from 5,685 units.

BOM:500570NSE:TMPV
Asia

Dian Tou Energy Acquires Baiyinhua Coal & Power for 11.1 Billion Yuan; Shares Down 4%

Inner Mongolia Dian Tou Energy (SHE:002128) fully acquired Baiyinhua Coal & Power for 11.1 billion yuan, according to a Tuesday disclosure on the Shenzhen bourse.The acquisition was made through share placement and capital injection.The company raised 4.50 billion yuan as part of the acquisition funds.The Chinese coal products maker's shares dropped 4% during the morning trade.

SHE:002128
Asia

Formosa Pharmaceuticals Gets Taiwan's Health Ministry for Pain Relief Drug; Shares Rise 3%

Formosa Pharmaceuticals (TPE:6838) received approval from Taiwan's Ministry of Health and Welfare for a drug to treat inflammation and pain following ocular surgery, according to a Monday Taiwan Exchange filing.Shares gained about 3% in Tuesday's late morning trade.The drug dubbed APP13007, is marketed as BYQLOVI Ophthalmic Suspension 0.05%.Financial details and accumulated development costs were not disclosed.

TPE:6838